​

Vaxcyte (PCVX) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChartTranscripts

PCVX Stock Forecast

Vaxcyte (PCVX) stock forecast, based on 11 Wall Street analysts, predicts a 12-month average price target of $122.33, with a high of $125.00 and a low of $120.00. This represents a 94.64% increase from the last price of $62.85.

$45 $61 $77 $93 $109 $125 High: $125 Avg: $122.33 Low: $120 Last Closed Price: $62.85

PCVX Stock Rating

Vaxcyte stock's rating consensus is Buy, based on 11 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 11 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 11 0 11 Strong Sell Sell Hold Buy Strong Buy

PCVX Price Target Upside V Benchmarks

TypeNameUpside
StockVaxcyte94.64%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts335
Avg Price Target$122.33$122.33$106.60
Last Closing Price$62.85$62.85$62.85
Upside/Downside94.64%94.64%69.61%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 26191--11
Sep, 26191--11
Aug, 26191--11
Jul, 26191--11
Jun, 26191--11
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 12, 2026Carter GouldCantor Fitzgerald$120.00$71.3868.11%90.93%
Oct 05, 2026Needham$122.00$72.3068.74%94.11%
Oct 05, 2026Seamus FernandezGuggenheim$125.00$56.48121.32%98.89%
Feb 25, 2026Tom ShraderBTIG$89.00$63.0441.18%41.61%
Nov 19, 2025David RisingerLeerink Partners$77.00$49.5355.46%22.51%
Nov 06, 2024Roger SongJefferies$146.00$106.7436.78%132.30%
Nov 06, 2024David RisingerLeerink Partners$135.00$106.7426.48%114.80%
Sep 10, 2024Salim SyedMizuho Securities$163.00$115.2841.39%159.35%
Sep 04, 2024Jason GerberryBank of America Securities$140.00$110.1527.10%122.75%
Sep 03, 2024David RisingerLeerink Partners$153.00$112.0436.56%143.44%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 12, 2026Cantor FitzgeraldOverweightOverweighthold
Oct 05, 2026BTIGBuyBuyhold
Oct 05, 2026NeedhamBuyBuyhold
Oct 05, 2026GuggenheimBuyBuyhold
Sep 28, 2026Bank of America SecuritiesBuyBuyhold
Mar 10, 2026JefferiesBuyBuyhold
Feb 25, 2026BTIGBuyBuyhold
Jan 07, 2026NeedhamBuyBuyhold
Nov 19, 2025Leerink PartnersOutperformOutperformhold
Aug 07, 2025Cowen & Co.BuyBuyhold

Financial Forecast

EPS Forecast

$-8 $-7 $-6 $-5 $-4 $-3 $-2 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-4.14$-3.80$-5.63---
Avg Forecast$-3.42$-3.91$-4.38$-4.63$-5.26$-3.30
High Forecast$-2.95$-3.49$-3.24$-2.78$-4.47$-3.30
Low Forecast$-3.77$-4.68$-6.15$-5.86$-7.10$-3.30
Surprise %21.05%-2.81%28.54%---

Revenue Forecast

$0 $100M $200M $300M $400M $500M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported------
Avg Forecast---$25.00M$97.50M$489.28M
High Forecast---$25.00M$97.50M$489.28M
Low Forecast---$25.00M$97.50M$489.28M
Surprise %------

Net Income Forecast

$-800M $-690M $-580M $-470M $-360M $-250M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-402.27M$-463.93M$-766.63M---
Avg Forecast$-326.57M$-396.52M$-559.26M$-540.52M$-559.77M$-320.43M
High Forecast$-286.38M$-338.69M$-315.15M$-270.50M$-434.43M$-320.43M
Low Forecast$-366.77M$-454.34M$-597.93M$-569.46M$-689.91M$-320.43M
Surprise %23.18%17.00%37.08%---

PCVX Forecast FAQ

Is Vaxcyte stock a buy?

Vaxcyte stock has a consensus rating of Buy, based on 11 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 11 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Vaxcyte is a favorable investment for most analysts.

What is Vaxcyte's price target?

Vaxcyte's price target, set by 11 Wall Street analysts, averages $122.33 over the next 12 months. The price target range spans from $120 at the low end to $125 at the high end, suggesting a potential 94.64% change from the previous closing price of $62.85.

How does Vaxcyte stock forecast compare to its benchmarks?

Vaxcyte's stock forecast shows a 94.64% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Vaxcyte over the past three months?

  • October 2026: 9.09% Strong Buy, 81.82% Buy, 9.09% Hold, 0% Sell, 0% Strong Sell.
  • September 2026: 9.09% Strong Buy, 81.82% Buy, 9.09% Hold, 0% Sell, 0% Strong Sell.
  • August 2026: 9.09% Strong Buy, 81.82% Buy, 9.09% Hold, 0% Sell, 0% Strong Sell.

What is Vaxcyte’s EPS forecast?

Vaxcyte's average annual EPS forecast for its fiscal year ending in December 2026 is $-4.63, marking a -17.76% decrease from the reported $-5.63 in 2025. Estimates for the following years are $-5.26 in 2027, and $-3.3 in 2028.

What is Vaxcyte’s revenue forecast?

Vaxcyte's average annual revenue forecast for its fiscal year ending in December 2026 is $25M, reflecting a 0% decrease from the reported $0 in 2025. The forecast for 2027 is $97.5M, and $489.28M for 2028.

What is Vaxcyte’s net income forecast?

Vaxcyte's net income forecast for the fiscal year ending in December 2026 stands at $-541M, representing a -29.49% decrease from the reported $-767M in 2025. Projections indicate $-560M in 2027, and $-320M in 2028.